Hyronate0.1%

Hyronate 0.1% is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy, and to simple analgesics, e.g., acetaminophen.

Drugs for Osteoarthritis

Sodium hyaluronate is a polysaccharide which functions as a tissue lubricant. It is widely used in ophthalmic surgery because it forms a viscoelastic solution in water which makes it a suitable substitute for aqueous and vitreous humour.

Hyronate 0.1% is administered by intra-articular injection. A treatment cycle consists of five injections given at weekly intervals. Some patients may experience benefit with three injections given at weekly intervals. Inject the full 2 ml in one knee only. If treatment is bilateral, a separate injection should be used for each knee.

The drug is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site.

The common side-effects include gastrointestinal complaints, injection site pain, knee swelling/effusion, local skin reactions (rash, ecchymosis), pruritus, and headache.

The safety and effectiveness of Hyronate 0.1% have not been established in pregnant women. It is not known if Hyronate 0.1% is excreted in human milk. The safety and effectiveness of Hyronate 0.1% have not been established in lactating mother. The safety and effectiveness of Hyronate 0.1% have not been demonstrated in children.

Use caution when injecting Hyronate 0.1% into patients who are allergic to avian proteins, feathers, and egg products. Strict aseptic administration technique must be followed. Remove joint effusion, if present, before injecting Hyronate 0.1%. Do not use the same syringe for removing joint effusion and for injecting Hyronate 0.1%. It is recommended that the patient avoid any strenuous activities or prolonged (i.e., more than 1 hour) weight-bearing activities such as jogging or tennis within 48 hours following the intra-articular injection.

No case of over dosage has been reported to date.

Hyronate injection should be stored in a cool (below 25° C) and dry place and protected from light. Protect from freezing.